sutthirat sutthisumdang
- Oppenheimer has initiated coverage of Vaxart (NASDAQ:VXRT) with an outperform rating, citing the company’s focus on oral vaccines.
- The investment bank said it’s optimistic about Vaxart’s (VXRT) differentiated oral vaccine platform, particularly its vaccine candidates for norovirus and COVID-19. It noted that oral vaccines could offer better solutions for infectious diseases like norovirus.
- Oppenheimer sees the norovirus market as highly attractive and worth around $5B to $10B. It added that it doesn’t view a recent setback for an intramuscular norovirus vaccine being developed by HilleVax (HLVX) as negatively reading across to Vaxart’s (VXRT) program.
- The investment bank set its price target for the stock at $4.
